2024
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-hospital deathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomes
2023
2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
DeCuir J, Zhu Y, Gaglani M, Ginde A, Mohr N, Gibbs K, Hager D, Frosch A, Mohamed A, Johnson N, Steingrub J, Peltan I, Martin E, Bender W, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Womack K, Swan S, McMorrow M, Self W, Surie D. 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.153. PMCID: PMC10677158, DOI: 10.1093/ofid/ofad500.153.Peer-Reviewed Original ResearchCOVID-19-associated hospitalizationRelative vaccine effectivenessVaccine effectivenessBooster doseSARS-CoV-2Hospitalized adultsIllness onsetDays of receiptCOVID-19 vaccination seriesCOVID-19-like illnessAdditional booster dosesAsahi Kasei PharmaMRNA vaccine effectivenessMultivariable logistic regressionHuman Services (HHS) regionsCase-control analysisUnvaccinated patientsVaccination seriesBooster dosesImmunization PracticesMRNA vaccinationAdults AgedRespiratory virusesAntigen testAdmission date